Table 1.

Immune checkpoint inhibitors and their targets in HCC.

Target	ICI	Clinical trial	Tumor type	Phase	Status	Enrollment
PD-L1	Atezolizumab	NCT04803994	Intermediate-stage HCC	III	recruiting	434
	Durvalumab	NCT05301842	Locoregional HCC	III	recruiting	525
	Sintilimab	NCT04220944	Unresectable HCC	I	recruiting	45
PD-1	Nivolumab	CheckMate-040	Advanced HCC	I-II	active	659
	Pembrolizumab	Keynote-224	Advanced HCC	II	active	156
	Tislelizumab	NCT03412773	Unresectable HCC	III	active	674
CTLA-4	Ipilimumab	NCT03682276	HCC	I-II	recruiting	32
	Tremelimumab	NCT01008358	Advanced HCC	II	completed	20
TIM-3	Cobolimab	NCT03680508	Advanced HCC	II	recruiting	42
LAG3	Relatilimab	None	None	None	None	None

HCC, hepatocellular carcinoma; ICI, immune checkpoint inhibitor; PD-1, programmed death 1; PD-L1, programmed death 1-ligand; CTLA-4, cytotoxic T lymphocyte-associated protein 4; TIM-3, T cell immunoglobulin and mucin domain containing-3; LAG-3, lymphocyte-activation gene 3.